|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-2-22
|
|
pubmed:abstractText |
Several new potent and selective A(2B) adenosine receptor antagonists have been prepared in which the aryl-amide moiety of the lead series, exemplified by 1a, has been replaced by bioisosteric bicyclic moieties. Although the majority of compounds had generally improved microsomal stability as compared to 1a, this was not translated into overall improvements in the pharmacokinetic profiles of a representative set of compounds.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1634-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20138516-Adenosine A2 Receptor Antagonists,
pubmed-meshheading:20138516-Amides,
pubmed-meshheading:20138516-Animals,
pubmed-meshheading:20138516-Anti-Inflammatory Agents,
pubmed-meshheading:20138516-Bicyclo Compounds,
pubmed-meshheading:20138516-Drug Discovery,
pubmed-meshheading:20138516-Humans,
pubmed-meshheading:20138516-Microsomes, Liver,
pubmed-meshheading:20138516-NADP,
pubmed-meshheading:20138516-Rats,
pubmed-meshheading:20138516-Receptor, Adenosine A2B
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement.
|
|
pubmed:affiliation |
Almirall Research Center, Almirall S.A., Ctra. Laureà Miró 408, E-08980 St. Feliu de Llobregat, Barcelona, Spain. paulroberteastwood@yahoo.co.uk
|
|
pubmed:publicationType |
Journal Article
|
